## TRMB: Trimble Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%); PEG 2.23 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.01)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Lucid Gravity Can Now Navigate City Canyons With Trimble Tech**
- Source: Benzinga | 20260106T132733 | Bullish | Relevance: 97%
- Lucid Group's stock rose following an announcement that its upcoming Gravity electric SUV will feature Trimble's advanced positioning technology. This collaboration will equip the Lucid Gravity with centimeter-level navigation accuracy, even in challenging urban environments. The Trimble positioning system, which combines satellite signals with inertial sensors, aims to significantly improve driver assistance and navigation reliability.

**2. AI Deal Turns Beaten-Down EV Stock Into A Market Mover**
- Source: Benzinga | 20260106T141045 | Neutral | Relevance: 65%
- Envirotech Vehicles Inc. (NASDAQ: EVTV) stock surged after the company signed an Amended and Restated Letter of Intent (LOI) to acquire AZIO AI Corporation through a merger. This deal, valuing AZIO AI at $480 million, would pivot EVTV towards advanced AI infrastructure and computing, with AZIO AI's CEO slated to become EVTV's CEO. The transaction is subject to due diligence, regulatory, board, and shareholder approvals.

**3. Ingersoll Rand Acquires Scinomix, Strengthens Life Sciences Portfolio**
- Source: Nasdaq | 20260106T160810 | Somewhat-Bullish | Relevance: 63%
- Ingersoll Rand Inc. (IR) recently acquired Scinomix, Inc., a leading automation workflow technology provider, to bolster its life sciences product portfolio. Scinomix's expertise in streamlining automation processes for lab equipment will expand Ingersoll Rand's presence in lucrative end markets such as pharmaceutical, clinical, and biotechnology. The acquisition aligns with Ingersoll Rand's growth strategy, despite the company currently holding a Zacks Rank #4 (Sell) due to rising costs and debt levels.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Keybanc | $99 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($2.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+0.6%)
- Blackrock Inc.: 8.2% (-5.4%)
- Morgan Stanley: 5.4% (-4.5%)
- State Street Corpora: 4.6% (+0.4%)
- Generation Investmen: 3.5% (-7.3%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.23 elevated, pricing in significant growth expectations. Forward P/E 23.6x stretched relative to 12% growth. Insider selling cluster ($2.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.4B |
| Beta | 1.59 |
| 52W Range | $52.91 - $87.50 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.23 |
| Forward P/E | 23.6 |
| Current P/E | 26.4 |
| YoY Growth | 11.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.3% to 1.6% (+2.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.56% (CS: 54) | Neutral |
| RSI_14 | 55.7 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 1.073x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $81.55
- **Stop Loss:** $78.01 (4.3% risk)
- **Target:** $85.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 310
- **Position Value:** $25,280.50
- **Portfolio %:** 25.28%
- **Risk Dollars:** $1,100.00
- **Risk Per Trade:** 1.10%
- **Modifiers:** L1 110% | L2 100% | Combined 1.10x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-18 (Est: $0.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.72 | $0.81 | +13.0% |
| 2025Q2 | $0.62 | $0.71 | +13.6% |
| 2025Q1 | $0.58 | $0.61 | +4.4% |
| 2024Q4 | $0.88 | $0.89 | +0.6% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*